Quarterly report [Sections 13 or 15(d)]

WARRANTS TO PURCHASE COMMON STOCK

v3.25.1
WARRANTS TO PURCHASE COMMON STOCK
 3 Months Ended
Mar. 31, 2025
Warrants To Purchase Common Stock  
WARRANTS TO PURCHASE COMMON STOCK

NOTE 14 – WARRANTS TO PURCHASE COMMON STOCK

 

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2025:

 

Exercise   Number   Expiration
Price   Outstanding   Date
$ 1,056.00     4,585   April 2029
$ 1,056.00     2,782   April 2029
$ 1,056.00     2,172   April 2029
$ 1,056.00     10,884   April 2029
$ 1,056.00     2,782   April 2025
$ 1,600.00     36   October 2028
$ 2,720.00     5,758   December 2028
$ 3,200.00     22   August 2028
        29,021    

 

During the three months ended March 31, 2025, 10,884, 5,758 (as the Company received FDA acceptance of our NDA filing), and 1 warrants with an exercise price of $1,056, $1,776 and $364,800, respectively, expired.

 

During the three months ended March 31, 2024, 4,701 prefunded common warrants were exercised.